Valneva SE - American Depositary Shares (NQ:VALN)

6.040 +0.225 (+3.87%)

Delayed Quote Updated: 9:30 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Valneva SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 ↗

June 05, 2025

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set for early 2026.

Via Benzinga

US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events ↗

May 12, 2025

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment.

Via Benzinga

Topics Death

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Insights Ahead: Valneva's Quarterly Earnings ↗

May 06, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

April 25, 2025

From Pomerantz LLP

Via GlobeNewswire

4 Analysts Have This To Say About Valneva ↗

February 19, 2025

Via Benzinga

Expert Ratings For Valneva ↗

October 11, 2024

Via Benzinga

In-Depth Examination Of 6 Analyst Recommendations For Valneva ↗

September 25, 2024

Via Benzinga

The Analyst Landscape: 6 Takes On Valneva ↗

September 03, 2024

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

April 21, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

April 17, 2025

From Pomerantz LLP

Via GlobeNewswire

12 Analysts Assess Valneva: What You Need To Know ↗

April 15, 2025

Via Benzinga

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine ↗

April 14, 2025

Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and endemic regions.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

April 12, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

April 07, 2025

From Pomerantz LLP

Via GlobeNewswire

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

April 04, 2025

From The Schall Law Firm

Via Business Wire

Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday ↗

April 03, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

March 30, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

March 26, 2025

From Pomerantz LLP

Via GlobeNewswire

Breaking Down Valneva: 6 Analysts Share Their Views ↗

March 21, 2025

Via Benzinga

Earnings Scheduled For March 20, 2025 ↗

March 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 31, 2025

Via Benzinga

Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot ↗

January 21, 2025

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

Via Benzinga

Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday ↗

December 19, 2024

Via Benzinga

Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults ↗

December 03, 2024

Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.

Via Benzinga

European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗

November 15, 2024

Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.

Via Benzinga

Palo Alto Networks To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday ↗

October 11, 2024

Via Benzinga

Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

September 13, 2024

Via Benzinga

Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study ↗

September 03, 2024

Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion...

Via Benzinga

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 19, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.